Prescription and method for treating female climacteric syndrome based on cooked pseudo-ginseng and caulis spatholobi

By strictly selecting and proportioning medicinal materials, and using advanced preparation technology, the problems of raw material pollution, uncertain ingredients and poor release control in existing drugs are solved, and the drug ingredients are clear, synergistic enhancement and uniform release are achieved, satisfying the different Effects of patient demand.

CN119055697AInactive Publication Date: 2024-12-03YUNNAN WENSHAN KUNQI PHARMA CORP LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411443726.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-16
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing drug formulas based on Cooked Panax notoginseng and Chicken Blood Vine have problems such as raw material contamination, uncertain composition, poor drug release control and individual differences, resulting in unstable efficacy and increased risk of side effects.

Method used

By strictly selecting medicinal materials, set the 2:3 ratio of cooked Panax notoginseng and Chicken Blood Vine, the 1:4 ratio of auxiliary medicinal materials, and perform detailed pretreatment and mixing, using a variety of advanced preparation technologies such as chitosan nanoparticles , liposome nanomaterials and spray-drying method to build the capsule shell, and combine high-precision microfluidic equipment to fill the capsule to ensure accurate control of the drug release speed and location.

Benefits of technology

It has achieved clear drug ingredients, enhanced synergy, uniform release, improved efficacy and reduced side effects, meeting the individual different needs of different patients, and providing a variety of preparation forms to improve treatment effect and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055697A_ABST
    Figure CN119055697A_ABST
Patent Text Reader

Abstract

The invention provides a formula and method for treating female climacteric syndrome based on cooked pseudo-ginseng and suberect spatholobus stem, and relates to the technical field of medicine production.The formula comprises cooked pseudo-ginseng, suberect spatholobus stem and auxiliary medicinal materials, the weight ratio of the cooked pseudo-ginseng to the suberect spatholobus stem is 2: 3, and the auxiliary medicinal materials are composed of angelica sinensis, radix paeoniae alba and radix rehmanniae preparata. According to the traditional Chinese medicine composition, the cooked pseudo-ginseng, the caulis spatholobi and the auxiliary medicinal materials are strictly selected, it is guaranteed that the raw materials are good in quality and free of mildewing and worm damage, the influence of pollution components on the medicine safety is reduced from the source, and the health of patients is guaranteed; meanwhile, the weight ratio of cooked pseudo-ginseng to suberect spatholobus stem is accurately set to be 2: 3, the total weight ratio of auxiliary medicinal materials (angelica sinensis, radix paeoniae alba and radix rehmanniae preparata) to the cooked pseudo-ginseng and suberect spatholobus stem is set to be 1: 4, and the medicinal materials are subjected to fine pretreatment including specific cleaning, airing, drying and smashing steps, so that the medicinal materials are clear and stable in component.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of pharmaceutical production, and in particular to a formula and method for treating female menopausal syndrome based on prepared Panax notoginseng and Millettia spatholobi. Background Art

[0002] The combination of Panax notoginseng and Millettia reticulata has a certain nourishing and regulating effect on the nervous system. They can improve nerve conduction function and alleviate the symptoms of insomnia and memory loss in menopausal women. Due to changes in hormone levels, menopausal women often affect the stability of the nervous system. This combination helps maintain the normal function of the nervous system and has a certain effect on alleviating the common anxiety and depression symptoms of menopausal women. By regulating the endocrine system and improving blood circulation, it indirectly affects the state of the nervous system, thereby making women's emotions more stable and improving their quality of life.

[0003] In the field of pharmaceutical production, the research and development of therapeutic drugs for female menopausal syndrome has always attracted much attention. Traditional treatment methods and drug preparations are diverse, involving a combination of multiple medicinal materials and different pharmaceutical processes. In the past, drug formulations for female menopausal syndrome would use some common Chinese medicinal materials, but the selection and processing of medicinal materials were relatively simple and extensive. For the application of Panax notoginseng and Millettia reticulata, there is no fine proportioning and strict pretreatment process. In terms of preparation, a more traditional process is used, with simple mixing and granulation to make capsules or tablets, and relatively little consideration is given to drug release control, stability and targeting.

[0004] The existing technology has the following problems in the production process of drugs based on Panax notoginseng and Millettia spatholobi as raw materials: 1. The raw materials used in existing drugs contain pollutants, which not only affects the safety of the drugs, but also poses a potential threat to the health of patients. At the same time, the composition of the raw materials is uncertain, resulting in unstable efficacy of the drugs, making it difficult to meet patients' expectations for treatment effects. In the process of mixing medicinal materials, the materials are not mixed according to the corresponding scientific proportions, so that the synergistic effect of the various components in the drugs cannot be fully exerted, affecting the therapeutic effect of the drugs on female menopausal syndrome. If the ratio between Panax notoginseng, Millettia spatholobi and auxiliary medicinal materials is inaccurate, the efficacy of the drugs in regulating endocrine and improving blood circulation will be greatly reduced; 2. Traditional preparation processes cannot meet the needs of modern drug treatment. Traditional capsule preparation simply fills the drug into the capsule shell, and lacks precise control over the drug release rate and location, resulting in uneven absorption of the drug in the body, affecting the efficacy while increasing the risk of side effects; 3. Existing drugs often use a unified formula and preparation form, without fully considering the individual differences of different patients, the severity of the disease, physical condition, and age factors. Therefore, a formula and method for the treatment of female menopausal syndrome based on Panax notoginseng and Millettia reticulata is needed to solve the above problems. Summary of the invention

[0005] 1. Technical issues to be solved

[0006] In view of the deficiencies in the prior art, the present invention provides a formula and method for treating female menopausal syndrome based on Radix Notoginseng and Spatholobus suberectus, which ensures that the raw materials are of excellent quality, free of mildew and insect-infested problems by strict selection of Radix Notoginseng, Spatholobus suberectus and auxiliary medicinal materials, reduces the impact of pollutants on drug safety from the source, and protects the health of patients. At the same time, the weight ratio of Radix Notoginseng and Spatholobus suberectus is accurately set to 2:3, the total weight ratio of auxiliary medicinal materials (Angelica sinensis, White Peony Root, Radix Rehmanniae Preparata) to Radix Notoginseng and Spatholobus suberectus is 1:4, and each medicinal material is carefully pretreated, including specific cleaning, airing, drying, and crushing steps, so that the medicinal material components are clear and stable. This can not only give full play to the efficacy of each medicinal material, but also allow them to synergize and enhance synergy, for example, in regulating endocrine and improving blood circulation, a more outstanding therapeutic effect is exerted, and the patient's expectations for the therapeutic effect are met, and the raw materials used in existing drugs are solved to have pollutants, which not only affects the safety of the drug, but also poses a potential threat to the patient's health. At the same time, the composition of the raw materials is uncertain, resulting in unstable efficacy of the drug, making it difficult to meet patients' expectations for treatment effects. In the process of mixing the medicinal materials, the materials were not mixed according to the corresponding scientific proportions, so that the synergistic effect of the various ingredients in the drug could not be fully exerted, affecting the therapeutic effect of the drug on female menopausal syndrome. If the ratio between Panax notoginseng, Millettia reticulata and auxiliary medicinal materials is inaccurate, the efficacy of the drug in regulating endocrine and improving blood circulation will be greatly reduced.

[0007] (II) Technical solution

[0008] To achieve the above purpose, the present invention is implemented by the following technical scheme: a formula and method for treating female menopausal syndrome based on cooked Panax notoginseng and Millettia spatholobi, comprising cooked Panax notoginseng, Millettia spatholobi and auxiliary medicinal materials, wherein the weight ratio of the cooked Panax notoginseng to Millettia spatholobi is 2:3, the auxiliary medicinal materials are composed of Angelica sinensis, White Peony Root and Rehmannia Glutinosa, and the total weight ratio of the auxiliary medicinal materials to the cooked Panax notoginseng and Millettia spatholobi is 1:4, and the cooked Panax notoginseng, Millettia spatholobi and auxiliary medicinal materials required for the preparation of the medicine are pretreated by the following steps:

[0009] Sp1. When pre-treating the cooked Panax notoginseng, first select Panax notoginseng with good quality, no mildew, and no insect infestation, rinse the impurities on the surface of Panax notoginseng with clean water to ensure that there is no soil attachment, and use a steamer to steam the Panax notoginseng. During the steaming, spread the Panax notoginseng flat in the steamer of the steamer. The steaming time of Panax notoginseng is 2-3 hours, and the temperature is controlled between 100℃-120℃. During the steaming process, observe the color and texture changes of Panax notoginseng. The color of Panax notoginseng gradually darkens from the grayish white of raw Panax notoginseng to the brown of cooked Panax notoginseng. At the same time, the texture of Panax notoginseng becomes soft. The steaming step of Panax notoginseng in this state is completed, and then the cooked Panax notoginseng is dried. Choose natural drying and low-temperature drying. When drying naturally, dry it in a well-ventilated, dry, clean place away from direct sunlight. Control the humidity within the range of 40%-60%. During the drying process, evenly spread the Panax notoginseng on a clean bamboo sieve and yarn surface. During the drying process, turn the Panax notoginseng regularly every 4-6 hours. When using low-temperature drying, choose a vacuum drying oven, put the Panax notoginseng in a professional vacuum drying oven, set the temperature between 40℃-50℃, and the drying time is 12-24 hours. During the drying process, constantly monitor the temperature and humidity to ensure that the Panax notoginseng can be dried evenly.

[0010] Sp2, after the dried Panax notoginseng is processed, the dried Panax notoginseng is ground into powder using a ball mill, and the crushed Panax notoginseng powder is screened through a sieve, and the crushed powder can pass through an 80-100 mesh sieve, and then the filtered Panax notoginseng powder is stored in a dry, cool, well-ventilated place, avoiding direct sunlight and high temperature environment;

[0011] Sp3, when the Millettia spatholobi is pretreated, first select Millettia spatholobi with solid texture, uniform thickness and no decay, then rinse the Millettia spatholobi with clean water, and soak the selected Millettia spatholobi in clean water for 15-30 minutes to fully soften the dust and impurities on the surface, gently stir during the soaking process to help impurities fall off and remove the dust and impurities on the surface, then sterilize by ultraviolet irradiation, and cut the Millettia spatholobi into segments according to pharmaceutical needs, and then dry and crush them, the drying and crushing methods of the Millettia spatholobi are the same as those of the Panax notoginseng, which are controlled between 40°C and 60°C, and the relative humidity is controlled between 40% and 60%, and the particle size after crushing is consistent with that of cooked Panax notoginseng;

[0012] Sp4, when the raw materials of Panax notoginseng and Millettia reticulata are prepared, they are mixed in a ratio of 2:3, and a blender is used to stir them during the mixing process to mix them into the main medicinal material;

[0013] Sp5. After that, the auxiliary medicinal materials including angelica sinensis, white peony root and cooked rehmannia are cleaned, air-dried, dried and crushed. The powders after crushing must be able to pass through 80-100 mesh sieves and remain consistent. The ratio of angelica sinensis, white peony root and cooked rehmannia is 1:1:1. After the main materials and auxiliary materials are obtained, they will be mixed in a ratio of 4:1.

[0014] Preferably, after the main medicinal materials and the auxiliary medicinal materials are mixed, a medicinal semi-finished product is formed, and then a microscope is used in conjunction with ImageJ image analysis software to perform a comprehensive inspection of the medicinal semi-finished product, and then a moisture meter is used in combination with near-infrared spectroscopy analysis technology to accurately measure the moisture content of the medicinal semi-finished product, and the moisture content is strictly controlled within the range of 8%-12%.

[0015] Preferably, when the semi-finished medicinal material that meets the test standards is to be produced into capsules, the specific steps are as follows:

[0016] Sp1. Material selection: Chitosan nanoparticles and liposome nanomaterials are the two options for capsule production materials;

[0017] Sp2. Preparation process: When chitosan nanoparticles are used as the material in capsule production, the chitosan solution is mixed with a cross-linking agent by an ion gel method, the concentration of the chitosan solution is between 0.1% and 2%, the cross-linking agent is tripolyphosphate, the mass ratio of the chitosan to the cross-linking agent is 2:1, the pH value of the chitosan solution is adjusted to be within the range of 4-6, and then the mixed solution is heated at a temperature between 20°C and 40°C. At the same time, during the mixing of the chitosan solution and the cross-linking agent, the mixed solution is stirred at a speed between 200-800rpm and a stirring time of 10-60 minutes. When rice is used as the material, the specific lipid components include phospholipids and cholesterol, the ratio of phospholipids to cholesterol is between 2:1, chloroform and methanol are selected as the organic solvent for dissolving the lipid components, the organic solvent containing the lipid components is evaporated on a rotary evaporator to form a uniform lipid film, the rotary evaporation temperature is between 30°C and 50°C, the vacuum degree is between -0.08MPa and -0.1MPa, and the evaporation time is 10-60 minutes, then the aqueous solution containing the drug is added to the lipid film for hydration, the hydration temperature is usually between 20°C and 40°C, and the hydration time is 10-60 minutes, so as to mix into a nanomaterial;

[0018] Sp3, then use the spray drying method to construct the capsule shell, first select the spray drying equipment and stirring equipment on the market, the spray drying equipment is equipped with an atomizer, a drying chamber, a hot air system and a collecting device, the nano material and the semi-finished medicinal material are fully mixed by the stirring equipment, the nano material and the semi-finished medicinal material are added to ethanol, the nano material and the semi-finished medicinal material and ethanol are fully mixed by the stirring equipment to form a uniform suspension, and the nano material is guaranteed to wrap the semi-finished medicinal material;

[0019] Sp4, after stirring and mixing, spray drying is performed. First, the mixed suspension is atomized into tiny droplets by an atomizer. The atomizer adopts a pressure nozzle. The atomized droplets enter the drying chamber and are dried in contact with hot air. The dried nanocapsule shells and drug particles are discharged from the drying chamber and collected by a collecting device. The collecting device adopts a cyclone separator and a bag filter;

[0020] Sp5. Use a particle size analyzer to analyze the particle size of the nanocapsule shell, and perform an appearance inspection on the collected nanocapsule shells to ensure that the capsule shells have a regular shape, a smooth surface, and no obvious defects and impurities.

[0021] Preferably, the capsule shell is constructed and then the capsule is filled. A high-precision microfluidic device is used for capsule filling. The high-precision microfluidic device comprises a microfluidic chip, a pump and a valve. The drug content of each capsule is 0.3 g. The microfluidic chip is made of polydimethylsiloxane. The pump is a syringe pump and the valve is a solenoid valve. The drug solution and the nanocapsule shell are introduced into the microfluidic chip respectively through the pump. A mixing channel is designed in the microfluidic chip. The drug solution and the nanocapsule shell are fully mixed through the action of fluid mechanics. After the mixed fluid enters the filling channel, the drug solution is filled into the nanocapsule shell through the action of fluid mechanics. Pressure sensors, flow sensors and optical sensors are used to monitor the parameters in the filling process in real time.

[0022] Preferably, after the capsule is filled, the capsule surface coating is treated, and the capsule surface coating is prepared by physical adsorption and chemical cross-linking. The specific preparation method is as follows:

[0023] Sp1, physical adsorption:

[0024] Solution immersion method: The nanocapsules are immersed in a solution containing the coating material, and the coating material is attached to the surface of the capsules by physical adsorption. The immersion temperature is between room temperature and 60°C, and a magnetic stirrer is used for rapid stirring. After the immersion is completed, the nanocapsules are taken out of the solution and separated by filtration and centrifugation.

[0025] Layer-by-layer self-assembly method: using layer-by-layer self-assembly technology, coating materials with opposite charges are alternately adsorbed on the surface of nanocapsules to form a multi-layer coating. The coating material with opposite charges can be selected, specifically cationic polymers, anionic polymers, polyelectrolytes and biomolecules. Through electrostatic interaction, the four materials of cationic polymers, anionic polymers, polyelectrolytes and biomolecules are alternately adsorbed on the surface of nanocapsules to form a multi-layer coating.

[0026] Sp2, chemical cross-linking:

[0027] Covalent cross-linking: using chemical reaction to cross-link the coating material with the nanocapsule shell to form a stable coating, and the cross-linking agent is selected from one of glutaraldehyde, diisocyanate and epichlorohydrin;

[0028] Click chemistry cross-linking: The coating material is cross-linked with the nanocapsule shell under mild conditions, and the copper-catalyzed azide-alkyne cycloaddition reaction (CuAAC) is used to cross-link the coating material with the nanocapsule shell to form a stable coating.

[0029] Preferably, when the semi-finished medicinal material that meets the inspection standards is to be made into tablets, a powder bed fusion printer is used for tableting, polyvinyl pyrrolidone (PVP) is used as the adhesive required for printing, and magnesium stearate lubricant is added. After printing, sandpaper and polishing agent are used to treat the surface of the tablets. During the printing process, an identification code is engraved on the surface of the tablet. The identification code can be in the form of any one of a bar code, a QR code, and a digital code, and the identification code contains the patient's name, medical record number, drug name, dosage, production date and expiration date.

[0030] Preferably, when the semi-finished medicinal material product that meets the inspection standards is to be made into pills, a centrifugal granulator is used to put the powder of the semi-finished medicinal material product into the centrifugal granulator, and the centrifugal force is generated by the high-speed rotating turntable to throw the drug powder to the periphery of the turntable. At the same time, air flow is introduced from the bottom or side of the turntable to form micro-pills under the combined action of centrifugal force and air flow. During the rotation process, the powder particles continuously collide, combine and grow to finally form uniform micro-pills. After forming, the micro-pill particles are irradiated with laser, and the size distribution of the particles is determined by measuring the scattering angle and intensity of the particles to the laser.

[0031] Preferably, when the semi-finished medicinal material that meets the inspection standards is to be made into an oral liquid, the supercritical fluid extraction technology is used to extract the semi-finished medicinal material. During the decoction process, an intelligent temperature control system is used to accurately control the decoction temperature between 80°C and 90°C for 2 hours. After decoction, the juice is filtered and extracted using an efficient membrane filtration technology to ensure the purity of the juice. The juice is then concentrated to a relative density of 1.1 using a vacuum concentration technology. The oral liquid is filled into a special light-proof and oxidation-proof container using aseptic filling technology, and the capacity of each bottle of oral liquid is 10 ml.

[0032] Preferably, carbon dioxide is selected as the supercritical fluid in the extraction process of the supercritical fluid extraction technology, and the extraction equipment includes a high-pressure pump, an extraction kettle and a separator. The high-pressure pump pressurizes the carbon dioxide to a supercritical state, the extraction kettle contains medicinal materials and supercritical carbon dioxide for extraction, and the separator separates the extracted solute from the supercritical fluid, and sets the extraction pressure and temperature, the pressure is between 10-30MPa, and the temperature is between 35-55°C.

[0033] Preferably, after the semi-finished medicinal materials are made into finished products, an intelligent quality traceability system is established to record in detail the sources of the medicinal materials, pretreatment steps, test results and production process of the preparations during the pharmaceutical manufacturing process.

[0034] (III) Beneficial effects

[0035] The present invention provides a formula and method for treating female menopausal syndrome based on Panax notoginseng and Millettia reticulata, which has the following beneficial effects:

[0036] In the present invention, by strictly selecting notoginseng, Millettia spatholobi and auxiliary medicinal materials, it is ensured that the raw materials are of excellent quality, free of mildew and insect-infested problems, and the impact of pollutants on drug safety is reduced from the source to ensure the health of patients. At the same time, the weight ratio of notoginseng and Millettia spatholobi is accurately set to 2:3, the total weight ratio of auxiliary medicinal materials (angelica, white peony, prepared rehmannia) to notoginseng and Millettia spatholobi is 1:4, and each medicinal material is carefully pretreated, including specific cleaning, airing, drying, and crushing steps, so that the medicinal material ingredients are clear and stable. This can not only give full play to the efficacy of each medicinal material, but also allow them to synergize and enhance synergy, for example, in regulating endocrine and improving blood circulation, a more outstanding therapeutic effect is exerted, meeting the patient's expectations for the therapeutic effect.

[0037] The present invention adopts a variety of advanced formulation technologies. Chitosan nanoparticles or liposome nanomaterials are used in capsule preparation. The capsule shell is constructed by ion gel method or specific liposome preparation process combined with spray drying method, and capsule filling is carried out by high-precision microfluidic equipment, so as to achieve precise control of drug release rate and location. This precise control can ensure uniform absorption of drugs in the body, improve efficacy and reduce the risk of side effects. For tablets, a powder bed melting printer is selected, suitable adhesives and lubricants are added, and surface treatment and coding are performed to meet personalized treatment needs; pills are made by using a centrifugal granulator combined with laser measurement to ensure the quality of micropills; oral liquids use supercritical fluid extraction technology and a series of precise decoction, filtration, concentration and aseptic filling processes to improve the stability and bioavailability of drugs, making the formulation process more in line with modern drug treatment needs.

[0038] The formula and method of the present invention fully consider the individual differences of patients, and provide a variety of preparation forms such as capsules, tablets, pills, and oral liquids for selection, so as to meet the needs of patients with different disease severity, physical conditions and age factors. For patients with dysphagia, oral liquids are more suitable; and for patients who need precise dosage control, capsules or tablets are a better choice. At the same time, a strict quality inspection system has been established throughout the pharmaceutical process, and multiple indexes are tested in all links from the pretreatment of medicinal materials to the finished product, including the content of active ingredients, microbial limits, heavy metals and pesticide residues. An intelligent quality traceability system is also used to record the entire pharmaceutical process in detail to ensure that the quality of each batch of drugs is stable, safe and reliable, and to provide patients with personalized and high-quality treatment plans to improve patients' treatment compliance and treatment effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 It is a flow chart of the drug production of the present invention. DETAILED DESCRIPTION

[0040] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the implementation of the present invention rather than all the embodiments. All other implementations obtained by ordinary technicians in this field based on the implementation of the present invention without creative work are within the scope of protection of the present invention. Specific embodiment one:

[0042] like Figure 1 As shown, a formula and method for treating female menopausal syndrome based on prepared Panax notoginseng and Millettia spatholobi comprises prepared Panax notoginseng, Millettia spatholobi and auxiliary medicinal materials, wherein the weight ratio of prepared Panax notoginseng to Millettia spatholobi is 2:3, the auxiliary medicinal materials are composed of Angelica sinensis, White Peony Root and Rehmannia Glutinosa, and the total weight ratio of the auxiliary medicinal materials to prepared Panax notoginseng and Millettia spatholobi is 1:4. The prepared Panax notoginseng, Millettia spatholobi and auxiliary medicinal materials required for the preparation of the medicine are pre-treated by the following steps:

[0043] Sp1. When pre-treating cooked Panax notoginseng, first select Panax notoginseng with good quality, no mildew or insect infestation, rinse the impurities on the surface of Panax notoginseng with clean water to ensure that there is no soil attachment, and steam the Panax notoginseng in a steamer. During steaming, spread the Panax notoginseng flat in the steamer of the steamer. The steaming time is 2-3 hours, and the temperature is controlled between 100℃-120℃. During the steaming process, observe the color and texture changes of Panax notoginseng. The color of Panax notoginseng gradually darkens from the grayish white of raw Panax notoginseng to the brownish brown of cooked Panax notoginseng. At the same time, the texture of Panax notoginseng will become soft. The steaming step of Panax notoginseng is completed in this state, and then the steamed cooked Panax notoginseng is dried. You can choose There are two ways to dry: natural drying and low-temperature drying. When drying naturally, dry it in a well-ventilated, dry, clean place away from direct sunlight. Control the humidity within the range of 40%-60%. During the drying process, evenly spread the cooked Panax notoginseng on a clean bamboo sieve and yarn surface. During the drying process, turn the cooked Panax notoginseng regularly every 4-6 hours. When using low-temperature drying, choose a vacuum drying oven, put the cooked Panax notoginseng in a professional vacuum drying oven, set the temperature between 40℃-50℃, and the drying time is 12-24 hours. During the drying process, constantly monitor the temperature and humidity to ensure that the cooked Panax notoginseng can be dried evenly.

[0044] Sp2. After the dried Panax notoginseng is processed, it is ground into powder using a ball mill. The crushed Panax notoginseng powder is screened through a sieve. The crushed powder must be able to pass through an 80-mesh to 100-mesh sieve. The filtered Panax notoginseng powder is then stored in a dry, cool, well-ventilated place, avoiding direct sunlight and high temperature environment.

[0045] Sp3, when pre-treating the Millettia spatholobi, first select the Millettia spatholobi with a solid texture, uniform thickness and no decay, then rinse the Millettia spatholobi with clean water, and soak the selected Millettia spatholobi in clean water for 15-30 minutes to fully soften the dust and impurities on the surface. During the soaking process, it can be gently stirred to help the impurities fall off and remove the dust and impurities on the surface. Then, it is sterilized by ultraviolet irradiation, and according to pharmaceutical needs, the Millettia spatholobi is cut into segments, and then dried and crushed. The drying and crushing methods of the Millettia spatholobi are the same as those of the Panax notoginseng, which are controlled between 40°C and 60°C, and the relative humidity is controlled between 40% and 60%. The particle size after crushing is consistent with that of cooked Panax notoginseng;

[0046] Sp4, when the raw materials of Panax notoginseng and Millettia reticulata are prepared, they are mixed in a ratio of 2:3, and a blender is used to stir them during the mixing process to mix them into the main medicinal material;

[0047] Sp5. After that, the auxiliary medicinal materials including angelica sinensis, white peony root and cooked rehmannia are cleaned, air-dried, dried and crushed. The powders after crushing must be able to pass through 80-100 mesh sieves and remain consistent. The ratio of angelica sinensis, white peony root and cooked rehmannia is 1:1:1. After the main materials and auxiliary materials are obtained, they will be mixed in a ratio of 4:1.

[0048] The above formula and the prepared medicine have the following advantages:

[0049] Ripening treatment improves drug efficacy: After the steaming process, the color and texture of Panax notoginseng change, which enhances the activity and bioavailability of the drug. For female patients with menopausal syndrome, cooked Panax notoginseng can play a better role in regulating endocrine and improving blood circulation.

[0050] Scientific ratio synergistic effect: Panax notoginseng and Millettia reticulata are matched in a ratio of 2:3, and the auxiliary herbs Angelica sinensis, White Peony Root, and Rehmannia glutinosa are composed in a specific ratio and mixed with the main herbs in a ratio of 1:4. This scientific ratio has been carefully studied and verified in practice, which can make the herbs work together to exert a stronger therapeutic effect. Angelica sinensis has the effect of nourishing blood and activating blood circulation, White Peony Root can calm the liver and relieve pain, nourish blood and regulate menstruation, and Rehmannia glutinosa nourishes yin and blood. Together with Panax notoginseng and Millettia reticulata, it can relieve the symptoms of menopause in women from multiple aspects.

[0051] Symptoms of menopausal women are related to dysfunction of the liver, kidney, and spleen. Angelica and white peony belong to the liver meridian. The liver-calming and analgesic effects of white peony help regulate the liver's function of dispersing qi. When the mood of menopausal women fluctuates greatly, it can play a role in calming the liver qi. Rehmannia glutinosa belongs to the kidney meridian, which can nourish yin and tonify the kidney, and has a nourishing effect on the kidney yin deficiency of menopausal women. Combining these herbs in a specific ratio is to synergistically improve the physical condition of menopausal women from the perspective of regulating the functions of the internal organs. When the functions of the liver, kidney, and spleen are coordinated with each other, the endocrine and metabolic physiological processes can be better regulated, thereby alleviating menopausal symptoms. The setting of this ratio is based on a comprehensive consideration of the meridians of each herb and its regulating effect on the functions of the internal organs, so that each herb can cooperate with each other in regulating the functions of the internal organs to achieve the best effect. When cooked Panax notoginseng and Millettia reticulata are matched in a ratio of 2:3, their chemical components enhance the regulating effect on the blood system through hydrogen bonds and π-π stacking.

[0052] The medicinal materials are crushed and screened to 80-100 mesh sieves to make the particles of the medicinal materials finer, which is conducive to improving the dissolution rate and bioavailability of the drug. During the preparation process, the fine powder can be better mixed with other ingredients to ensure the accurate content of the drug ingredients in each preparation, thereby improving the treatment effect and safety.

[0053] The formula and method can be adjusted according to the specific condition and physical condition of the patient. For example, capsules, tablets, pills or oral liquids can be selected in the form of preparations to meet the needs of different patients. At the same time, by accurately controlling the proportion and dosage of drug ingredients, personalized treatment plans can be achieved, the pertinence and effectiveness of treatment can be improved, and the use of natural Chinese medicinal materials for treatment has fewer side effects than chemical drugs. During the pretreatment process, strict quality control and hygiene standards ensure the safety of medicinal materials. In addition, through scientific preparation methods and quality inspection systems, the safety and reliability of the products are further guaranteed, so that patients can be more assured during the treatment process. Different preparation forms provide patients with a variety of choices, which are convenient for patients to take according to their preferences and actual conditions. Capsules and tablets are easy to carry and take, and oral liquids have a good taste, which is suitable for some patients with dysphagia. At the same time, the application of intelligent packaging systems and identification codes facilitates patients to understand drug information and usage records, and improves patients' medication compliance.

[0054] The specific parameters of the medicinal materials are shown in the following table:

[0055]

[0056] Specific embodiment 2:

[0058] A formula and method for treating female menopausal syndrome based on cooked Panax notoginseng and Millettia reticulata. The main medicinal materials and auxiliary medicinal materials are mixed to form a medicinal material semi-finished product. Then, a microscope is used in conjunction with ImageJ image analysis software to comprehensively detect the medicinal material semi-finished product. Then, a moisture meter is used in combination with near-infrared spectroscopy analysis technology to accurately measure the moisture content of the medicinal material semi-finished product, and the moisture content is strictly controlled within the range of 8%-12%.

[0059] Microscopes can provide high-resolution images, allowing us to observe the microstructure of semi-finished medicinal materials. Through the microscope, we can clearly see the size, shape, color and presence of impurities of medicinal material particles. For mixed semi-finished products of Panax notoginseng, Millettia reticulata and auxiliary medicinal materials, the microscope can help determine whether the ingredients are evenly mixed and whether there are incompletely crushed particles. Through ImageJ image analysis software, images under the microscope can be quantitatively analyzed, the size and shape parameters of particles can be measured, the distribution of particles can be calculated, and specific features in the image can be identified and analyzed.

[0060] The moisture analyzer uses the loss on drying method to determine the moisture content. The loss on drying method is to heat the sample to evaporate the water in it, and then measure the weight loss of the sample to calculate the moisture content. Specific embodiment three:

[0062] A formula and method for treating female menopausal syndrome based on cooked Panax notoginseng and Millettia reticulata, when the semi-finished medicinal materials that meet the standards are tested and produced into capsules, the specific steps are as follows:

[0063] Sp1. Material selection: Chitosan nanoparticles and liposome nanomaterials are the two options for capsule production materials;

[0064] Sp2. Preparation process: When chitosan nanoparticles are used as the material in capsule production, the chitosan solution is mixed with the cross-linking agent by the ion gel method, the concentration of the chitosan solution is between 0.1% and 2%, the cross-linking agent is tripolyphosphate, the mass ratio of chitosan to the cross-linking agent is 2:1, the pH value of the chitosan solution is adjusted within the range of 4-6, and then the mixed solution is heated at a temperature between 20°C and 40°C. At the same time, during the mixing of the chitosan solution and the cross-linking agent, the mixed solution is stirred at a speed between 200-800rpm and a stirring time of 10-60 minutes. When the material is a phospholipid, the specific lipid components include phospholipids and cholesterol, the ratio of phospholipids to cholesterol is between 2:1, chloroform and methanol are selected as the organic solvent for dissolving the lipid components, the organic solvent containing the lipid components is evaporated on a rotary evaporator to form a uniform lipid film, the rotary evaporation temperature is between 30°C and 50°C, the vacuum degree is -0.08MPa to -0.1MPa, and the evaporation time is 10-60 minutes, then the aqueous solution containing the drug is added to the lipid film for hydration, the hydration temperature is usually between 20°C and 40°C, and the hydration time is 10-60 minutes, so as to mix into a nanomaterial;

[0065] Sp3, then use the spray drying method to construct the capsule shell, first select the spray drying equipment and stirring equipment on the market, the spray drying equipment is equipped with an atomizer, a drying chamber, a hot air system and a collecting device, the nano material and the semi-finished medicinal material are fully mixed by the stirring equipment, the nano material and the semi-finished medicinal material are added to ethanol, the nano material and the semi-finished medicinal material and ethanol are fully mixed by the stirring equipment to form a uniform suspension, and the nano material is guaranteed to wrap the semi-finished medicinal material;

[0066] Sp4, after stirring and mixing, spray drying is performed. First, the mixed suspension is atomized into tiny droplets by an atomizer. The atomizer adopts a pressure nozzle. The atomized droplets enter the drying chamber and are dried in contact with hot air. The dried nanocapsule shells and drug particles are discharged from the drying chamber and collected by a collecting device. The collecting device adopts a cyclone separator and a bag filter;

[0067] Sp5. Use a particle size analyzer to analyze the particle size of the nanocapsule shell, and perform an appearance inspection on the collected nanocapsule shells to ensure that the capsule shells have a regular shape, a smooth surface, and no obvious defects and impurities.

[0068] The following is a detailed supplement to the steps of producing capsules:

[0069] Material selection

[0070] Chitosan nanoparticles advantages:

[0071] Biocompatibility: Chitosan is a natural polysaccharide with good biocompatibility and little irritation to human tissue, making it suitable for use in pharmaceutical preparations.

[0072] Stability: Chitosan nanoparticles can prevent drugs from being oxidized, hydrolyzed or photodegraded.

[0073] Controlled release performance: Controlled release of drugs can be achieved by adjusting the chemical structure and preparation process of chitosan.

[0074] Advantages of liposome nanomaterials:

[0075] Drug loading capacity: Liposomes have a high drug loading capacity and can encapsulate a large number of drug molecules, which is of great significance for some poorly soluble drugs or diseases that require high-dose treatment.

[0076] Biodegradability: Liposomes are made of biodegradable materials and can be gradually metabolized and eliminated in the body without causing long-term burden on the human body.

[0077] pH adjustment: Use an acid-base regulator, sodium hydroxide or hydrochloric acid, to adjust the pH value of the chitosan solution within the range of 4-6 during the pH adjustment process. Specific embodiment four:

[0079] A formula and method for treating female menopausal syndrome based on Panax notoginseng and Millettia reticulata. After the capsule shell is constructed, the capsule is filled. A high-precision microfluidic device is used for capsule filling. The high-precision microfluidic device includes a microfluidic chip, a pump and a valve. Each capsule contains 0.3 grams of medicine. The microfluidic chip is made of polydimethylsiloxane. The pump is a syringe pump, and the valve is a solenoid valve. The drug solution and the nanocapsule shell are respectively introduced into the microfluidic chip through the pump. A mixing channel is designed in the microfluidic chip. The drug solution and the nanocapsule shell are fully mixed through fluid mechanics. After the mixed fluid enters the filling channel, the drug solution is filled into the nanocapsule shell through fluid mechanics. A pressure sensor, a flow sensor and an optical sensor are used to monitor the parameters in the filling process in real time.

[0080] The following details are added during the capsule filling process:

[0081] 1. Advantages of high-precision microfluidic equipment

[0082] Precise control: Microfluidic equipment achieves precise control of fluids, ensuring that the drug content of each capsule is 0.3 grams. Through precise adjustment of the syringe pump and solenoid valve components, the flow rate and flow velocity of the drug solution and the nanocapsule shell are accurately controlled, thereby ensuring the accuracy of filling.

[0083] Efficient mixing: The mixing channel design in the microfluidic chip uses fluid mechanics to achieve sufficient mixing of the drug solution and the nanocapsule shell.

[0084] Real-time monitoring: The use of pressure sensors, flow sensors and optical sensors monitors the parameters of the filling process, pressure, flow and filling status of the capsule in real time.

[0085] 2. Design and fabrication of microfluidic chips

[0086] Material selection: Polydimethylsiloxane (PDMS) is a commonly used microfluidic chip material with good biocompatibility, optical transparency and processability. It can be processed by soft lithography to produce complex microchannel structures.

[0087] Chip structure design: The design of the microfluidic chip should take into account the flow characteristics of the drug solution and the nanocapsule shell as well as the requirements for mixing and filling. The length, width, and shape of the mixing channel should be optimized to ensure that the drug solution and the nanocapsule shell can be fully mixed. The design of the filling channel should ensure that the drug solution can be smoothly filled into the nanocapsule shell without leakage or blockage.

[0088] Manufacturing process: Microfluidic chips are usually made using soft lithography technology. First, make a mold with the required microchannel structure. The mold can be made on a silicon wafer or other materials using photolithography technology. Then, pour the PDMS prepolymer on the mold, and demold it after curing to obtain a microfluidic chip. During the manufacturing process, attention should be paid to controlling the temperature, time and pressure parameters to ensure the quality and performance of the chip.

[0089] Through the above supplementary content, we can have a more comprehensive understanding of the application and key technologies of high-precision microfluidic equipment in the capsule filling process, and improve the accuracy, efficiency and quality of capsule filling. Specific embodiment five:

[0091] A formula and method for treating female menopausal syndrome based on prepared Panax notoginseng and Millettia reticulata. After the capsules are filled, the surface coating of the capsules is treated. Physical adsorption and chemical cross-linking are used in the preparation process of the coating on the surface of the capsules. The specific preparation method is as follows:

[0092] Sp1, physical adsorption:

[0093] Solution immersion method: The nanocapsules are immersed in a solution containing the coating material, and the coating material is attached to the surface of the capsules by physical adsorption. The immersion temperature is between room temperature and 60°C, and a magnetic stirrer is used for rapid stirring. After the immersion is completed, the nanocapsules are taken out of the solution and separated by filtration and centrifugation.

[0094] Layer-by-layer self-assembly method: using layer-by-layer self-assembly technology, coating materials with opposite charges are alternately adsorbed on the surface of nanocapsules to form a multi-layer coating. The coating material with opposite charges can be selected, specifically cationic polymers, anionic polymers, polyelectrolytes and biomolecules. Through electrostatic interaction, the four materials of cationic polymers, anionic polymers, polyelectrolytes and biomolecules are alternately adsorbed on the surface of nanocapsules to form a multi-layer coating.

[0095] Sp2, chemical cross-linking:

[0096] Covalent cross-linking: using chemical reaction to cross-link the coating material with the nanocapsule shell to form a stable coating, and the cross-linking agent is selected from one of glutaraldehyde, diisocyanate and epichlorohydrin;

[0097] Click chemistry cross-linking: The coating material is cross-linked with the nanocapsule shell under mild conditions, and the copper-catalyzed azide-alkyne cycloaddition reaction (CuAAC) is used to cross-link the coating material with the nanocapsule shell to form a stable coating. Specific embodiment six:

[0099] A formula and method for treating female menopausal syndrome based on prepared Panax notoginseng and Millettia reticulata. When a semi-finished medicinal material that has met the testing standards is to be made into tablets, a powder bed melting printer is used for tablet making, polyvinyl pyrrolidone (PVP) is used as the adhesive required for printing, and magnesium stearate lubricant is added. After printing, sandpaper and polishing agent are used to treat the surface of the tablet. During the printing process, an identification code is engraved on the surface of the tablet. The identification code can be in any form of a bar code, a QR code, or a digital code, and the identification code contains the patient's name, medical record number, drug name, dosage, production date, and expiration date.

[0100] The following is a detailed supplement to the tableting process:

[0101] Polyvinylpyrrolidone (PVP) as a binder:

[0102] Function: PVP acts as a binder in tablet manufacturing. It can bind medicinal powder together to form solid tablets. PVP has good water solubility and biocompatibility and will not adversely affect the activity and safety of the drug.

[0103] Magnesium stearate as a lubricant:

[0104] Function: Magnesium stearate acts as a lubricant in tablet manufacturing. It can reduce the friction between medicinal powder and printing equipment, making the printing process smoother. Magnesium stearate can also improve the surface smoothness of tablets and improve the quality and appearance of tablets.

[0105] Tablet surface treatment methods and purposes

[0106] Sandpaper treatment:

[0107] Method: Use sandpaper to gently polish the surface of the printed tablet to remove burrs and uneven parts on the surface to make the tablet surface smoother. The particle size of the sandpaper should be selected according to the hardness and surface requirements of the tablet. Sandpaper of about 2000 mesh can be selected.

[0108] Polishing agent treatment:

[0109] Method: After sandpaper treatment, the tablet surface can be further polished with a polishing agent. The polishing agent can be pharmaceutical grade paraffin or silicone oil. Apply the polishing agent evenly on the tablet surface, and then use a polishing machine or manual polishing. The polishing agent can also form a protective film on the tablet surface to prevent the drug from contacting the external environment and improve the stability of the drug. Specific embodiment seven:

[0111] A formula and method for treating female menopausal syndrome based on prepared Panax notoginseng and Millettia reticulata. When a semi-finished medicinal material product that has reached the detection standard is to be made into pills, a centrifugal granulator is used to put the powder of the semi-finished medicinal material product into the centrifugal granulator, and a centrifugal force is generated by a high-speed rotating turntable to throw the drug powder to the periphery of the turntable. At the same time, air flow is introduced from the bottom or side of the turntable to form micro-pills under the combined action of centrifugal force and air flow. During the rotation process, the powder particles continuously collide, combine and grow to finally form uniform micro-pills. After forming, the micro-pill particles are irradiated with laser, and the size distribution of the particles is determined by measuring the scattering angle and intensity of the particles to the laser. Specific embodiment eight:

[0113] A formula and method for treating female menopausal syndrome based on cooked Panax notoginseng and Millettia reticulata. When a semi-finished medicinal material that has reached the testing standard is to be made into an oral liquid, the semi-finished medicinal material is extracted using supercritical fluid extraction technology. During the decoction process, an intelligent temperature control system is used to accurately control the decoction temperature between 80°C and 90°C for 2 hours. After decoction, the juice is filtered and extracted using an efficient membrane filtration technology to ensure the purity of the juice. The juice is then concentrated to a relative density of 1.1 using a vacuum concentration technology. The oral liquid is filled into a special light-proof and oxidation-proof container using aseptic filling technology. The capacity of each bottle of oral liquid is 10 ml.

[0114] The following are additional details on the process of making oral liquid:

[0115] 1. In addition to carbon dioxide, other supercritical fluids such as ethane and propane can also be considered for supercritical fluid extraction. However, carbon dioxide is widely used in the pharmaceutical field because of its relatively low critical temperature and pressure, non-toxicity, non-flammability, and good chemical stability. It has a density and solubility similar to that of liquid in the supercritical state, and has the diffusivity and permeability of gas, and can efficiently extract the effective ingredients in medicinal materials.

[0116] The extraction equipment is as follows:

[0117] High-pressure pump: It is the key equipment to pressurize carbon dioxide to a supercritical state. It should have high-precision pressure control and stable output performance. The material of the high-pressure pump needs to be corrosion-resistant to cope with the corrosion caused by carbon dioxide under high pressure. Stainless steel can be used and special anti-corrosion treatment can be performed.

[0118] Extraction kettle: The design of the extraction kettle should take into account the convenience of loading and unloading of medicinal materials, as well as the impact of the internal structure on fluid flow and extraction effect. Usually, a stirring device or a special fluid distributor will be installed inside the extraction kettle to ensure that the medicinal materials are in full contact with supercritical carbon dioxide. The pressure resistance of the extraction kettle must meet safety standards and have good sealing performance to prevent carbon dioxide leakage.

[0119] Separator: The function of the separator is to separate the extracted solute from the supercritical fluid. Its structure can adopt a multi-stage separation method to improve the separation efficiency. Two stages can be set: preliminary separation and fine separation. In the preliminary separation, most of the carbon dioxide is turned into gas by reducing the pressure, and a small amount of solute is carried into the fine separation stage, and the solute is further completely separated by temperature or adsorption.

[0120] 2. Decoction process:

[0121] Temperature sensor: Use high-precision thermocouples or thermistors as temperature sensors, and their measurement accuracy should be able to reach ±0.5℃ or higher to ensure accurate monitoring of the decoction temperature. The temperature sensor should be installed in a suitable position in the decoction container to accurately reflect the actual temperature of the medicinal liquid. The sensor can be installed near the center of the medicinal liquid and not in direct contact with the medicinal materials to avoid interference with the temperature measurement by the medicinal materials.

[0122] Controller: The controller of the intelligent temperature control system usually adopts a microprocessor or a programmable logic controller (PLC). According to the signal fed back by the temperature sensor, it is compared with the preset temperature range (80℃-90℃), and the control signal is calculated through the algorithm to adjust the power or on / off of the heating element. The controller should have a fast response speed and stable control performance, and be able to adjust the temperature in time to avoid excessive temperature fluctuations. When the temperature approaches the upper limit of 90℃, the controller should quickly reduce the heating power or stop heating; when the temperature is lower than the lower limit of 80℃, the heating power should be increased in time to keep the temperature within the set range.

[0123] Heating element: Choose the right heating element, electric heating tube or steam heating coil. The power of the heating element should be reasonably configured according to the size of the decoction container and the amount of liquid medicine to ensure that the liquid medicine can be heated to the set temperature within the specified time and keep the temperature stable. At the same time, the distribution of the heating elements should be even to avoid local overheating or overcooling. For larger decoction containers, multiple heating elements can be evenly distributed at the bottom or around the container to improve the uniformity of heating.

[0124] Material: The decoction container should be made of a material that is chemically stable and not prone to chemical reactions with the liquid medicine, such as stainless steel, glass or ceramic. Stainless steel has good thermal conductivity and durability, but be careful to choose stainless steel models that meet food and drug hygiene standards; glass is transparent and easy to observe the decoction process, but it is fragile and has relatively poor thermal conductivity; ceramic has good chemical stability, but slow heat transfer and is heavy. Choose the appropriate decoction container material based on actual production needs and cost considerations.

[0125] Capacity and shape: The capacity of the decoction container should be selected according to the production scale and the amount of medicinal materials to be decocted each time, ensuring that there is enough space to hold the medicinal liquid and fully decoct it. The shape of the container should be conducive to the circulation of the medicinal liquid and uniform heating. A container with a round or oval bottom and a guide device or stirring device inside can promote the flow of the medicinal liquid and improve the decoction effect.

[0126] Sealing performance: The decoction container should have good sealing performance to prevent the volatilization of the medicinal liquid and the entry of external impurities during the decoction process. It can be sealed with a sealing cover or a sealing ring to ensure that the pressure and temperature in the container are relatively stable during the decoction process. At the same time, the sealing cover should be equipped with a vent hole to discharge the steam generated during the decoction process to avoid excessive pressure in the container.

[0127] 3. Membrane filtration uses one of the following three methods, which can be selected according to actual process requirements:

[0128] Microfiltration membrane: The pore size of microfiltration membrane is generally between 0.1-10μm, and it is mainly used to remove suspended matter, bacteria, yeast and other large particle impurities in the liquid medicine. The materials of microfiltration membrane are cellulose ester, polycarbonate, and polytetrafluoroethylene, which have the characteristics of fast filtration speed, low resistance and low cost, but the precision of microfiltration membrane is relatively low, and it cannot effectively remove some small molecular impurities and effective ingredients.

[0129] Ultrafiltration membrane: The pore size of ultrafiltration membrane is between 1-100nm, which can remove macromolecular proteins, polysaccharides, and colloidal impurities in the liquid medicine, while retaining some small molecular effective ingredients. The materials of ultrafiltration membrane include polysulfone, polyacrylonitrile, and polyethersulfone, which have high filtration accuracy and selectivity. However, the filtration resistance of ultrafiltration membrane is relatively large, requiring high pressure drive, and it is easily contaminated, requiring regular cleaning and maintenance.

[0130] Nanofiltration membrane: The pore size of nanofiltration membrane is between 0.5-2nm, which is between ultrafiltration membrane and reverse osmosis membrane. It can selectively separate small molecular organic matter and divalent ions in the liquid medicine, and also has a certain interception effect on some effective ingredients. The materials of nanofiltration membrane are mainly polyamide and cellulose acetate, which have the advantages of low operating pressure, low energy consumption, and good permeability to monovalent ions and small molecular organic matter. However, the price of nanofiltration membrane is relatively high, and the water quality requirements are strict.

[0131] Select the appropriate filtration pressure according to the type of membrane and the properties of the drug solution. Too high pressure will cause damage to the membrane and increase clogging; too low pressure will reduce the filtration speed and efficiency. Generally speaking, the operating pressure of microfiltration membrane is between 0.1-0.3MPa, the operating pressure of ultrafiltration membrane is between 0.2-0.6MPa, and the operating pressure of nanofiltration membrane is between 0.5-1.5MPa. In actual operation, the optimal filtration pressure can be found by gradually increasing the pressure while observing the flow rate and quality changes of the filtrate.

[0132] Cleaning and maintenance: Clean and maintain the membrane regularly to extend its service life and ensure filtering effect. Cleaning methods include physical cleaning and chemical cleaning. Physical cleaning can be done by backwashing and ultrasonic cleaning to remove loose impurities on the membrane surface; chemical cleaning uses specific cleaning agents, acids, alkalis, and oxidants to remove stubborn dirt and organic pollution on the membrane surface. During the cleaning process, attention should be paid to the concentration, temperature, and cleaning time of the cleaning agent to avoid damage to the membrane. At the same time, the membrane should be regularly tested for performance, flux, and retention rate to promptly detect damage or performance degradation of the membrane and replace or repair it.

[0133] 4. Parameter control of vacuum concentration includes:

[0134] Vacuum degree: Vacuum degree is one of the key parameters that affect the concentration effect and efficiency. Generally speaking, the higher the vacuum degree, the lower the boiling point of the liquid medicine and the faster the concentration speed. However, too high a vacuum degree will cause the loss of some volatile components in the liquid medicine, and will also increase the energy consumption and investment cost of the equipment. In actual operation, the appropriate vacuum degree range should be selected according to the properties of the liquid medicine and the concentration requirements, usually between -0.08MPa and -0.1MPa. The vacuum degree can be adjusted by adjusting the vacuum pump's pumping rate or controlling the leakage of the vacuum system.

[0135] Temperature: The concentration temperature should be controlled within a range that can ensure the stability of the active ingredients in the liquid medicine and quickly evaporate the water. Generally speaking, the temperature should not exceed 60°C. For some liquid medicines with high content of heat-sensitive ingredients, the temperature should be lower. The concentration temperature can be controlled by adjusting the temperature of the heating medium (steam pressure) or by using indirect heating (hot water jacket heating). At the same time, pay attention to monitoring the temperature changes of the liquid medicine during the concentration process to avoid local overheating that may cause component damage.

[0136] Concentration time: The concentration time depends on the initial concentration, volume, vacuum and temperature of the drug solution. Under the premise of ensuring the concentration effect, the concentration time should be shortened as much as possible to reduce the loss of active ingredients and improve production efficiency. The concentration end point can be determined by real-time monitoring of the concentration or relative density of the drug solution. When the relative density of the drug solution reaches 1.1, the concentration process is stopped.

[0137] Stirring speed: During the concentration process, proper stirring of the liquid medicine can promote heat and mass transfer, prevent local overheating and uneven concentration of the liquid medicine. The stirring speed should be selected according to the viscosity of the liquid medicine and the type of evaporator, generally between 20-100rpm. Too fast stirring speed will cause the liquid medicine to foam, affecting the concentration effect; too slow stirring speed will not play a good stirring role. A variable frequency stirrer can be used to adjust the stirring speed according to the different stages of the concentration process. Specific embodiment nine:

[0139] A formula and method for treating female menopausal syndrome based on Panax notoginseng and Millettia reticulata. Carbon dioxide is selected as a supercritical fluid in the extraction process using supercritical fluid extraction technology. The extraction equipment includes a high-pressure pump, an extraction kettle and a separator. The high-pressure pump pressurizes the carbon dioxide to a supercritical state. The extraction kettle contains medicinal materials and supercritical carbon dioxide for extraction. The separator separates the extracted solute from the supercritical fluid, and the extraction pressure and temperature are set. The pressure is between 10-30MPa and the temperature is between 35-55°C.

[0140] The following is a further supplement to the details of the supercritical fluid extraction process:

[0141] Before using carbon dioxide, its purity needs to be strictly tested. Generally, gas chromatography analysis technology is used to ensure that the purity of carbon dioxide meets pharmaceutical grade standards, for example, the purity is not less than 99.9%. The presence of impurities will affect the extraction effect and even have an adverse effect on the quality of the drug. Common impurities include water, oxygen, and hydrocarbons, and their content must be strictly controlled within the specified range.

[0142] Since water and oxygen react chemically with the ingredients in the medicinal materials or affect the extraction process, the carbon dioxide needs to be dehydrated and deoxygenated. Dehydration can be done by molecular sieve adsorption, where the carbon dioxide passes through an adsorption column equipped with molecular sieves to remove the water in it and reduce the water content to an extremely low level, for example, less than 0.01%.

[0143] Deoxygenation can be achieved by using a deoxidizer or by purging the carbon dioxide with an inert gas before extraction. The carbon dioxide can be passed through a device equipped with a metal reducing agent (palladium catalyst) to reduce and remove the oxygen in it, ensuring that the oxygen content is below the specified value, below 0.1%, to improve the stability of the extraction process and the quality of the drug. Specific embodiment ten:

[0145] The following is a detailed explanation of the explanation that has been verified by research and practice:

[0146] Pharmacological experiments:

[0147] At the cellular level, using cell culture technology, human umbilical vein endothelial cells or ovarian granulosa cells were co-cultured with drug extracts to observe cell proliferation, apoptosis, and changes in gene expression. It was also observed how much of Panax notoginseng and Millettia reticulata extracts could regulate vascular endothelial cells, promote the release of nitric oxide, and improve vasodilation function.

[0148] In animal experiments, a variety of animal models were constructed, including menopausal rat models and mouse models. Animals were gavaged and injected with drugs to observe behavioral changes, changes in physiological indicators, and differences in histopathology. During the experiment, the drug was able to improve the hot flashes of animals (by measuring temperature change indicators) and regulate hormone levels (detecting the levels of estrogen and progesterone in serum), which verified the effectiveness and mechanism of action of the drug and provided experimental basis for further clinical application.

[0149] Animal experiment design: experimental group and control group,

[0150] Experimental group: received the formula of Panax notoginseng and Millettia reticulata.

[0151] Control group: received saline or drug without active ingredients.

[0152] Animal Type: Adult male and female rats (10 per group) were used.

[0153] Dosage: Oral administration, dosage is calculated based on body weight (for example: 5 mg per kilogram of body weight).

[0154] Observation time: The observation period is 4 weeks, with evaluation once a week.

[0155] Observation indicators:

[0156] Physiological indicators:

[0157] Weight changes, activity level (using a photoelectric counter to record the number of activities), appetite (food intake was recorded daily);

[0158] Biochemical indicators:

[0159] Blood sample testing (hormone levels, inflammatory factors), urine analysis;

[0160] Behavioral assessment:

[0161] Anxiety test (open field test), depression test (forced swimming test);

[0162] Histopathological examination: sampling and tissue section observation;

[0163] Physiological index score:

[0164] Weight change: increase ≥10% (effective), 0-10% (partially effective), decrease (ineffective);

[0165] Activity level: increase ≥20% (effective), 0-20% (partially effective), decrease (ineffective);

[0166] Appetite: increased by ≥10% (effective), 0-10% (partially effective), decreased (ineffective);

[0167] Biochemical index score:

[0168] Hormone levels return to normal (effective), slightly abnormal (partially effective), significantly abnormal (ineffective)

[0169] Behavioral Assessment Scoring:

[0170] Anxiety and depression behaviors were significantly improved (effective), slightly improved (partially effective), or not improved (ineffective);

[0171] Histopathological examination:

[0172] Normal tissue structure (effective), slightly damaged (partially effective), severely damaged (ineffective);

[0173]

[0174]

[0175]

[0176] Clinical case observation:

[0177] In clinical practice, we first conducted a small-scale case observation. A certain number of female patients with menopausal syndrome were selected and given drug treatment based on Panax notoginseng and Millettia reticulata. The improvement of the patients' symptoms was followed up and observed, and the changes in the number of hot flashes, sleep quality, and emotional state indicators of the patients before and after treatment were recorded. Through preliminary case observations, it was found that after taking the medication, the patients' menopausal symptoms were alleviated to varying degrees, the number of hot flashes decreased, the sleep quality improved, and the mood tended to stabilize, indicating that the drug is suitable for the treatment of menopausal syndrome in women.

[0178] The control group alone was a placebo of equal dose, the main components of which were water and starch.

[0179] The scoring criteria for each symptom are as follows:

[0180] 1. Hot flashes

[0181] 0 points: no hot flashes.

[0182] 1 point: Occurs occasionally and lasts for a very short time (<1 minute).

[0183] 2 points: Occurs occasionally and lasts for a short time (1-5 minutes).

[0184] 3 points: 1-2 times a week, medium duration (5-10 minutes). 4 points: 3-4 times a week, long duration (10-20 minutes). 5 points: almost every day, long duration (>20 minutes).

[0185] 6 points: multiple times a day, affecting daily life.

[0186] 7 points: severe hot flashes, accompanied by obvious discomfort.

[0187] 8 points: Occurs frequently and cannot be controlled.

[0188] 9 points: Continuous state, seriously affecting work and social life.

[0189] 10 points: Extreme hot flashes, completely unable to lead a normal life.

[0190] 2. Insomnia

[0191] 0 points: No insomnia, good sleep quality.

[0192] 1 point: Occasionally has difficulty falling asleep, usually recovers.

[0193] 2 points: Difficulty falling asleep 1-2 times a week, with minor impact.

[0194] 3 points: Difficulty falling asleep 3-4 times a week, affecting daily activities.

[0195] 4 points: Difficulty falling asleep 5-6 times a week, and measures need to be taken.

[0196] 5 points: Difficulty falling asleep almost every day, affecting sleep quality.

[0197] 6 points: Difficulty maintaining sleep and waking up frequently.

[0198] 7 points: Severe insomnia, requiring drug intervention.

[0199] 8 points: Waking up multiple times and having difficulty falling asleep again.

[0200] 9 points: Complete insomnia and extreme fatigue.

[0201] 10 points: Unable to fall asleep, seriously affecting the quality of life.

[0202] 3. Anxiety

[0203] 0 points: no anxiety, emotional stability.

[0204] 1 point: Occasionally feel nervous, but does not affect daily life.

[0205] 2 points: Mildly anxious, occasionally feeling uneasy.

[0206] 3 points: Moderate anxiety, affecting concentration.

[0207] 4 points: Frequent anxiety that affects daily work.

[0208] 5 points: Obvious anxiety, and relief measures are needed.

[0209] 6 points: Persistent anxiety that affects social activities.

[0210] 7 points: Severe anxiety, often unable to relax.

[0211] 8 points: Severe anxiety, requiring medication.

[0212] 9 points: Uncontrollable anxiety and extreme discomfort.

[0213] 10 points: Continuous anxiety, seriously affecting life. The evaluation of treatment effect is based on the change in the patient's score after treatment: Effective: The score after treatment is reduced by ≥50%.

[0214] Partially effective: The score decreased by 20%-49% after treatment.

[0215] Ineffective: score decreased by <20% or no change after treatment;

[0216]

[0217]

[0218] It should be noted that, in this article, the relational terms such as first and second are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that the process, method, article or equipment including a series of elements includes not only those elements, but also includes other elements not explicitly listed, or also includes elements inherent to such process, method, article or equipment. In the absence of further restrictions, the elements defined by the statement "comprising a reference structure" do not exclude the existence of other identical elements in the process, method, article or equipment including the elements.

[0219] Although the implementation of the present invention has been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the invention, the scope of the invention being defined by the appended claims and their equivalents.

Claims

1. A formula and method for treating female menopausal syndrome based on prepared Panax notoginseng and Millettia spatholobi, comprising prepared Panax notoginseng, Millettia spatholobi and auxiliary medicinal materials, characterized in that: The weight ratio of the prepared Panax notoginseng to Millettia spatholobi is 2:3, the auxiliary medicinal materials are composed of Angelica sinensis, White Peony Root, and Rehmannia glutinosa, and the total weight ratio of the auxiliary medicinal materials to the prepared Panax notoginseng and Millettia spatholobi is 1:

4. The prepared Panax notoginseng, Millettia spatholobi and auxiliary medicinal materials required for the preparation of the medicine are pre-treated by the following steps: Sp1. When pre-treating the cooked Panax notoginseng, first select Panax notoginseng with good quality, no mildew, and no insect infestation, rinse the impurities on the surface of Panax notoginseng with clean water to ensure that there is no soil attachment, and use a steamer to steam the Panax notoginseng. During the steaming, spread the Panax notoginseng flat in the steamer of the steamer. The steaming time of Panax notoginseng is 2-3 hours, and the temperature is controlled between 100℃-120℃. During the steaming process, observe the color and texture changes of Panax notoginseng. The color of Panax notoginseng gradually darkens from the grayish white of raw Panax notoginseng to the brown of cooked Panax notoginseng. At the same time, the texture of Panax notoginseng becomes soft. The steaming step of Panax notoginseng in this state is completed, and then the cooked Panax notoginseng is dried. Choose natural drying and low-temperature drying. When drying naturally, dry it in a well-ventilated, dry, clean place away from direct sunlight. Control the humidity within the range of 40%-60%. During the drying process, evenly spread the Panax notoginseng on a clean bamboo sieve and yarn surface. During the drying process, turn the Panax notoginseng regularly every 4-6 hours. When using low-temperature drying, choose a vacuum drying oven, put the Panax notoginseng in a professional vacuum drying oven, set the temperature between 40℃-50℃, and the drying time is 12-24 hours. During the drying process, constantly monitor the temperature and humidity to ensure that the Panax notoginseng can be dried evenly. Sp2, after the dried Panax notoginseng is processed, the dried Panax notoginseng is ground into powder using a ball mill, and the crushed Panax notoginseng powder is screened through a sieve, and the crushed powder can pass through an 80-100 mesh sieve, and then the filtered Panax notoginseng powder is stored in a dry, cool, well-ventilated place, avoiding direct sunlight and high temperature environment; Sp3, when the Millettia spatholobi is pretreated, first select Millettia spatholobi with solid texture, uniform thickness and no decay, then rinse the Millettia spatholobi with clean water, and soak the selected Millettia spatholobi in clean water for 15-30 minutes to fully soften the dust and impurities on the surface, gently stir during the soaking process to help impurities fall off and remove the dust and impurities on the surface, then sterilize by ultraviolet irradiation, and cut the Millettia spatholobi into segments according to pharmaceutical needs, and then dry and crush them, the drying and crushing methods of the Millettia spatholobi are the same as those of the Panax notoginseng, which are controlled between 40°C and 60°C, and the relative humidity is controlled between 40% and 60%, and the particle size after crushing is consistent with that of cooked Panax notoginseng; Sp4, when the raw materials of Panax notoginseng and Millettia reticulata are prepared, they are mixed in a ratio of 2:3, and a blender is used to stir them during the mixing process to mix them into the main medicinal material; Sp5. After that, the auxiliary medicinal materials including angelica sinensis, white peony root and cooked rehmannia are cleaned, air-dried, dried and crushed. The powders after crushing must be able to pass through 80-100 mesh sieves and remain consistent. The ratio of angelica sinensis, white peony root and cooked rehmannia is 1:1:

1. After the main materials and auxiliary materials are obtained, they will be mixed in a ratio of 4:

1.

2. A formula and method for treating female menopausal syndrome based on Radix Notoginseng and Millettia Spatholobi according to claim 1, characterized in that: After the main medicinal materials and the auxiliary medicinal materials are mixed, a medicinal semi-finished product is formed. Then, a microscope is used in conjunction with ImageJ image analysis software to perform a comprehensive inspection of the medicinal semi-finished product. Then, a moisture meter is used in combination with near-infrared spectroscopy analysis technology to accurately measure the moisture content of the medicinal semi-finished product, and the moisture content is strictly controlled within the range of 8%-12%.

3. A formula and method for treating female menopausal syndrome based on Radix Notoginseng and Millettia Spatholobi according to claim 2, characterized in that: When the semi-finished medicinal materials that meet the test standards are to be produced into capsules, the specific steps are as follows: Sp1. Material selection: Chitosan nanoparticles and liposome nanomaterials are the two options for capsule production materials; Sp2. Preparation process: When chitosan nanoparticles are used as the material in capsule production, the chitosan solution is mixed with a cross-linking agent by an ion gel method, the concentration of the chitosan solution is between 0.1% and 2%, the cross-linking agent is tripolyphosphate, the mass ratio of the chitosan to the cross-linking agent is 2:1, the pH value of the chitosan solution is adjusted to be within the range of 4-6, and then the mixed solution is heated at a temperature between 20°C and 40°C. At the same time, during the mixing of the chitosan solution and the cross-linking agent, the mixed solution is stirred at a speed between 200-800rpm and a stirring time of 10-60 minutes. When rice is used as the material, the specific lipid components include phospholipids and cholesterol, the ratio of phospholipids to cholesterol is between 2:1, chloroform and methanol are selected as the organic solvent for dissolving the lipid components, the organic solvent containing the lipid components is evaporated on a rotary evaporator to form a uniform lipid film, the rotary evaporation temperature is between 30°C and 50°C, the vacuum degree is between -0.08MPa and -0.1MPa, and the evaporation time is 10-60 minutes, then the aqueous solution containing the drug is added to the lipid film for hydration, the hydration temperature is usually between 20°C and 40°C, and the hydration time is 10-60 minutes, so as to mix into a nanomaterial; Sp3, then use the spray drying method to construct the capsule shell, first select the spray drying equipment and stirring equipment on the market, the spray drying equipment is equipped with an atomizer, a drying chamber, a hot air system and a collecting device, the nano material and the semi-finished medicinal material are fully mixed by the stirring equipment, the nano material and the semi-finished medicinal material are added to ethanol, the nano material and the semi-finished medicinal material and ethanol are fully mixed by the stirring equipment to form a uniform suspension, and the nano material is guaranteed to wrap the semi-finished medicinal material; Sp4, after stirring and mixing, spray drying is performed. First, the mixed suspension is atomized into tiny droplets by an atomizer. The atomizer adopts a pressure nozzle. The atomized droplets enter the drying chamber and are dried in contact with hot air. The dried nanocapsule shells and drug particles are discharged from the drying chamber and collected by a collecting device. The collecting device adopts a cyclone separator and a bag filter; Sp5. Use a particle size analyzer to analyze the particle size of the nanocapsule shell, and perform an appearance inspection on the collected nanocapsule shells to ensure that the capsule shells have a regular shape, a smooth surface, and no obvious defects and impurities.

4. A formula and method for treating female menopausal syndrome based on Radix Notoginseng and Millettia Spatholobi according to claim 3, characterized in that: After the capsule shell is constructed, the capsule is filled. A high-precision microfluidic device is used for capsule filling. The high-precision microfluidic device includes a microfluidic chip, a pump and a valve. The drug content of each capsule is 0.3 grams. The microfluidic chip is made of polydimethylsiloxane. The pump is a syringe pump, and the valve is a solenoid valve. The drug solution and the nanocapsule shell are respectively introduced into the microfluidic chip through the pump. A mixing channel is designed in the microfluidic chip. The drug solution and the nanocapsule shell are fully mixed through the action of fluid mechanics. After the mixed fluid enters the filling channel, the drug solution is filled into the nanocapsule shell through the action of fluid mechanics. Pressure sensors, flow sensors and optical sensors are used to monitor the parameters in the filling process in real time.

5. A formula and method for treating female menopausal syndrome based on Radix Notoginseng and Millettia Spatholobi according to claim 4, characterized in that: After the capsule is filled, the capsule surface coating is treated. The capsule surface coating is prepared by physical adsorption and chemical cross-linking. The specific preparation method is as follows: Sp1, physical adsorption: Solution immersion method: The nanocapsules are immersed in a solution containing the coating material, and the coating material is attached to the surface of the capsules by physical adsorption. The immersion temperature is between room temperature and 60°C, and a magnetic stirrer is used for rapid stirring. After the immersion is completed, the nanocapsules are taken out of the solution and separated by filtration and centrifugation. Layer-by-layer self-assembly method: using layer-by-layer self-assembly technology, coating materials with opposite charges are alternately adsorbed on the surface of nanocapsules to form a multi-layer coating. The coating material with opposite charges can be selected, specifically cationic polymers, anionic polymers, polyelectrolytes and biomolecules. Through electrostatic interaction, the four materials of cationic polymers, anionic polymers, polyelectrolytes and biomolecules are alternately adsorbed on the surface of nanocapsules to form a multi-layer coating. Sp2, chemical cross-linking: Covalent cross-linking: using chemical reaction to cross-link the coating material with the nanocapsule shell to form a stable coating, and the cross-linking agent is selected from one of glutaraldehyde, diisocyanate and epichlorohydrin; Click chemistry cross-linking: The coating material is cross-linked with the nanocapsule shell under mild conditions, and the copper-catalyzed azide-alkyne cycloaddition reaction (CuAAC) is used to cross-link the coating material with the nanocapsule shell to form a stable coating.

6. The formula and method for treating female menopausal syndrome based on Radix Notoginseng and Millettia Spatholobi according to claim 3, characterized in that: When the semi-finished medicinal material that meets the inspection standards is to be made into tablets, a powder bed fusion printer is used for tableting, polyvinyl pyrrolidone (PVP) is used as the adhesive required for printing, and magnesium stearate lubricant is added. After printing, sandpaper and polishing agent are used to treat the surface of the tablets. During the printing process, an identification code is engraved on the surface of the tablet. The identification code can be in the form of any one of a bar code, a QR code, and a digital code, and the identification code contains the patient's name, medical record number, drug name, dosage, production date and expiration date.

7. The formula and method for treating female menopausal syndrome based on Radix Notoginseng and Millettia Spatholobi according to claim 3, characterized in that: When the semi-finished medicinal material product that meets the inspection standards is to be made into pills, a centrifugal granulator is used to put the powder of the semi-finished medicinal material product into the centrifugal granulator, and a centrifugal force is generated by a high-speed rotating turntable to throw the drug powder to the periphery of the turntable. At the same time, air flow is introduced from the bottom or side of the turntable to form micro-pills under the combined action of centrifugal force and air flow. During the rotation process, the powder particles continuously collide, combine and grow to finally form uniform micro-pills. After forming, the micro-pill particles are irradiated with laser, and the size distribution of the particles is determined by measuring the scattering angle and intensity of the particles to the laser.

8. The formula and method for treating female menopausal syndrome based on Radix Notoginseng and Millettia Spatholobi according to claim 3, characterized in that: When the semi-finished medicinal materials that meet the inspection standards are to be made into oral liquid, supercritical fluid extraction technology is used to extract the semi-finished medicinal materials. During the decoction process, an intelligent temperature control system is used to accurately control the decoction temperature between 80°C and 90°C for 2 hours. After decoction, the juice is filtered and extracted using efficient membrane filtration technology to ensure the purity of the juice. The juice is then concentrated to a relative density of 1.1 using vacuum concentration technology. The oral liquid is filled into a special light-proof and oxidation-proof container using aseptic filling technology. The capacity of each bottle of oral liquid is 10 ml.

9. A formula and method for treating female menopausal syndrome based on Radix Notoginseng and Millettia Spatholobi according to claim 8, characterized in that: In the extraction process of the supercritical fluid extraction technology, carbon dioxide is selected as the supercritical fluid. The extraction equipment includes a high-pressure pump, an extraction kettle and a separator. The high-pressure pump pressurizes the carbon dioxide to a supercritical state. The extraction kettle contains medicinal materials and supercritical carbon dioxide for extraction. The separator separates the extracted solute from the supercritical fluid, and sets the extraction pressure and temperature. The pressure is between 10-30MPa and the temperature is between 35-55°C.

10. The formula and method for treating female menopausal syndrome based on Radix Notoginseng and Millettia Spatholobi according to claim 1, characterized in that: After the semi-finished medicinal materials are made into finished products, an intelligent quality traceability system is established to record in detail the sources of the medicinal materials, pretreatment steps, test results and production process of the preparations during the pharmaceutical manufacturing process.